NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - NICE TAG TA322

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - NICE TAG TA322

1.1 Lenalidomide is recommended as an option, within its marketing authorisation, that is for treating transfusion‑dependent anaemia caused by low or intermediate‑1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, with the following condition:

  • The drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company.

http://www.nice.org.uk/guidance/ta322

Site by Devopa
© Copyright 2019 NHS. All rights reserved.